Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Biometrics
|
December 29, 2000
Bayesian estimators for conditional hazard functions
I W McKeague, M Tighiouart
British Journal of Cancer
|
November 13, 2008
Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma
H Zhang, L Su, S Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2019
Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
Z S Zumsteg, M Luu, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2018
Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
Z S Zumsteg, M Luu, S Kim, et al.
British Journal of Cancer
|
January 17, 2013
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
R D Harvey, T K Owonikoko, C M Lewis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Biometrics
|
December 29, 2000
Bayesian estimators for conditional hazard functions
I W McKeague, M Tighiouart
British Journal of Cancer
|
November 13, 2008
Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma
H Zhang, L Su, S Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2019
Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
Z S Zumsteg, M Luu, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2018
Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
Z S Zumsteg, M Luu, S Kim, et al.
British Journal of Cancer
|
January 17, 2013
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
R D Harvey, T K Owonikoko, C M Lewis, et al.
Page
of 1